Institute of Digestive Disease and Department of Medicine & Therapeutics, State Key Laboratory of Digestive Disease, LKS Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, Hong Kong.
Adv Exp Med Biol. 2018;1061:55-62. doi: 10.1007/978-981-10-8684-7_5.
Obesity increases death rates of all cancers including non-alcoholic fatty liver disease (NAFLD)-related hepatocellular carcinoma (NAFLD-HCC). NAFLD is considered as hepatic manifestation of metabolic syndrome and is a multi-system disease. Recent prevalence studies have intensively reported the association of obesity, metabolic risk factors and HCC incidence and mortality. Mechanistic studies suggested that immune response, PI3K/AKT/mTOR/PTEN pathway, mitochondrial dysfunction and genetic alterations are important mediators in the progression of NAFLD-HCC from metabolic disorder. In this book chapter, we attempt to collate current research on NAFLD-HCC that lead to our understandings on how metabolic disorders may intersect with cancer development. We also discussed the prevention options of NAFLD-HCC in view of obesity and metabolic disorder. These studies have extended our knowledge on the complicated mechanism of NAFLD and HCC, and provided the prevention options of NAFLD-HCC in patients with obesity and metabolic diseases.
肥胖增加了所有癌症的死亡率，包括非酒精性脂肪性肝病（NAFLD）相关的肝细胞癌（NAFLD-HCC）。NAFLD 被认为是代谢综合征的肝脏表现，是一种多系统疾病。最近的流行性病学研究集中报道了肥胖、代谢危险因素与 HCC 发病率和死亡率之间的关系。机制研究表明，免疫反应、PI3K/AKT/mTOR/PTEN 通路、线粒体功能障碍和遗传改变是 NAFLD-HCC 从代谢紊乱进展的重要介质。在这一章中，我们试图整理目前关于 NAFLD-HCC 的研究，以了解代谢紊乱如何与癌症的发生相互交叉。我们还讨论了鉴于肥胖和代谢紊乱，NAFLD-HCC 的预防选择。这些研究扩展了我们对 NAFLD 和 HCC 复杂机制的认识，并为肥胖和代谢性疾病患者的 NAFLD-HCC 提供了预防选择。
